share_log

Earnings Call Summary | Streamline Health Solutions(STRM.US) Q3 2024 Earnings Conference

Earnings Call Summary | Streamline Health Solutions(STRM.US) Q3 2024 Earnings Conference

業績會總結 | Streamline Health Solutions(STRm.US) 2024年第三季度業績會
富途資訊 ·  12/18 00:12  · 電話會議

The following is a summary of the Streamline Health Solutions, Inc. (STRM) Q3 2024 Earnings Call Transcript:

以下是Streamline Health Solutions, Inc. (STRM) 2024財年第3季度業績會錄音的摘要:

Financial Performance:

財務表現:

  • Streamline reported Q3 FY2024 revenue of $4.4 million, down from $6.1 million in Q3 FY2023, impacted by client non-renewals despite new SaaS contracts.

  • SaaS revenue for Q3 FY2024 was $2.9 million, comprising 66% of the total revenue.

  • Net loss for Q3 FY2024 was $2.5 million, a reduction from a net loss of $11.9 million in Q3 FY2023, reflecting lower total revenues, higher interest expenses offset by reductions in SG&A and R&D expenses.

  • Booked SaaS ACV as of October 31st, 2024, totaled $14.1 million, with $12 million implemented.

  • Streamline報告2024財年第3季度營業收入爲440萬,低於2023財年第3季度的610萬,這受到客戶不續約的影響,儘管簽署了新的SaaS-雲計算合同。

  • 2024財年第3季度SaaS-雲計算營業收入爲290萬,佔總營業收入的66%。

  • 2024財年第3季度淨虧損爲250萬,相較於2023財年第3季度的1190萬淨虧損有所減少,反映出總營業收入下降,利息支出增加,但受到銷售和一般管理費用及研發費用減少的抵消。

  • 截至2024年10月31日,已記錄的SaaS-雲計算年度合同價值(ACV)總計爲1410萬,其中1200萬已經實施。

Business Progress:

業務進展:

  • Streamline launched a quality module for eValuator during Q3, expanding its service offerings.

  • Developed best practice manuals and enhanced client relationships through focused efforts and direct resources.

  • Streamline plans to achieve a $15.5 million SaaS ARR by first half of FY2025.

  • Streamline在第三季度推出了eValuator的質量模塊,擴展了其服務產品。

  • 制定最佳實踐手冊,通過專注的努力和直接的資源增強客戶關係。

  • Streamline計劃在2025財年上半年實現1550萬SaaS-雲計算年經常性收入。

Opportunities:

機會:

  • The growth and implementation of the eValuator and RevID platforms, including the new quality module, bode well for expanding client relationships and penetrating new markets.

  • Plans to unlock significant value through displacement campaigns, partnerships, and leveraging existing client successes to gain new clients.

  • eValuator和RevID平台的增長和實施,包括新的質量模塊,對擴展客戶關係和進入新市場具有良好前景。

  • 計劃通過置換活動、合作伙伴關係以及利用現有客戶的成功來獲得新客戶,從而解鎖顯著的價值。

Risks:

風險:

  • Lower total revenue impacted by non-renewals of client contracts posing a risk to anticipated growth and survival in a competitive sector.

  • Reliance on advancing new module developments and penetrating new markets amid economic and sector-specific challenges.

  • 受到客戶合同未續簽影響,總營業收入下降,給預期的增長和在競爭激烈的板塊中生存帶來了風險。

  • 在經濟和特定板塊挑戰中,依賴於推進新模塊開發和進入新市場。

More details: Streamline Health Solutions IR

更多詳情:Streamline Health Solutions IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更全面的細節,請參閱IR網站。 文章僅供投資者參考,不構成任何指導或推薦建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論